Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › biktarvy

biktarvy

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of biktarvy

4 trials tracked of biktarvy: 4 in phase 3 or 4 and 3 with published results. The most-cited published study has 9 citations.

4Trials tracked
4Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 2 Phase 3 2
  1. Phase 3 Effects of Biktarvy on CFR in Stable HIV Patients Completed · 9 cited
  2. Phase 4 Combo-PEP: Multipurpose Prevention of Post-Exposure Prophylaxis Regimens Completed
  3. Phase 3 The Late Presenter Treatment Optimisation Study Completed
  4. Phase 4 Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM Completed

Showing the 4 most-cited and recently-updated of 4 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Once-Weekly Islatravir and Lenacapavir Demonstrate Noninferiority to Daily B/F/TAF for HIV Suppression
Infectious Disease RCT
Once-Weekly Islatravir and Lenacapavir Demonstrate Noninferiority to Daily B/F/TAF for HIV Suppression Trial shows weekly islatravir and lenacapavir maintain HIV suppression
A Phase 3 trial confirms that once-weekly islatravir-lenacapavir maintains viral suppression comparable to daily B/F/TAF.
A new once-weekly pill combination showed similar success to daily treatment in keeping HIV levels suppressed for adults with the virus.
Oct 4, 2026